PROTECTIVE EFFECT OF AN SGLT2 INHIBITOR ON ER STRESS THROUGH REDUCTION OF ECTOPIC LIPID DEPOSITION IN RENAL TUBULES IN OBESE MICE

被引：0

作者：

Takata, Tomoaki ^{[1
]}

Hosokawa, Kohshiro ^{[1
]}

Sugihara, Takaaki ^{[1
]}

Matono, Tomomitsu ^{[1
]}

Koda, Masahiko ^{[1
]}

Kanda, Tsutomu ^{[1
]}

Ogawa, Masaya ^{[1
]}

Ida, Ayami ^{[1
]}

Mae, Yukari ^{[1
]}

Yamamoto, Marie ^{[1
]}

Iyama, Takuji ^{[1
]}

Fukuda, Satoko ^{[1
]}

Isomoto, Hajime ^{[1
]}

机构：

[1] Tottori Univ, Fac Med, Div Med & Clin Sci, Yonago, Tottori, Japan

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

P0933

引用

页码：1260 / 1260

页数：1

共 50 条

[41] SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction
Ahmed, Ahmed S.
Mona, Marwa M.
Abdel-Kareem, Mona A.
Elsisy, Rasha A.
BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
[42] SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Nephropathy by Inhibiting High Glucose-induced Oxidative Stress in Diabetic Akita Mice
Hatanaka, Takashi
Ogawa, Daisuke
Terami, Naoto
Nishii, Naoko
Nakatsuka, Atsuko
Eguchi, Jun
Wada, Jun
DIABETES, 2015, 64 : A140 - A140
[43] SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Chino, Yukihiro
Samukawa, Yoshishige
Sakai, Soichi
Nakai, Yasuhiro
Yamaguchi, Jun-ichi
Nakanishi, Takeo
Tamai, Ikumi
BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (07) : 391 - 404
[44] Empagliflozin, an SGLT2 inhibitor, prevented palmitate-induced lipotoxicity through enhanced fatty acid oxidation and reduced stress signals
Kim, T.
Kim, Y.
Park, S.
Kim, Y.
Choi, S. -E.
Son, Y.
An, S.
Jeon, J.
Lee, N.
Han, S.
Kim, H.
Kim, D.
Lee, K. -W.
DIABETOLOGIA, 2024, 67 : S315 - S315
[45] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Gallo, Linda A.
Ward, Micheal S.
Fotheringham, Amelia K.
Zhuang, Aowen
Borg, Danielle J.
Flemming, Nicole B.
Harvie, Ben M.
Kinneally, Toni L.
Yeh, Shang-Ming
McCarthy, Domenica A.
Koepsell, Hermann
Vallon, Volker
Pollock, Carol
Panchapakesan, Usha
Forbes, Josephine M.
SCIENTIFIC REPORTS, 2016, 6
[46] The Effect of Luseogliflozin (TS-071), a Selective SGLT2 Inhibitor, on Pharmacodynamics and Pharmacokinetics in Japanese Type 2 Diabetic Subjects With Renal Impairment
Haneda, Masakazu
Seino, Yutaka
Sasaki, Takashi
Fukatsu, Atsushi
Samukawa, Yoshishige
Sakai, Soichi
Sato, Yuri
Watanabe, Takashi
DIABETES, 2012, 61 : A273 - A273
[47] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Linda A. Gallo
Micheal S. Ward
Amelia K. Fotheringham
Aowen Zhuang
Danielle J. Borg
Nicole B. Flemming
Ben M. Harvie
Toni L. Kinneally
Shang-Ming Yeh
Domenica A. McCarthy
Hermann Koepsell
Volker Vallon
Carol Pollock
Usha Panchapakesan
Josephine M. Forbes
Scientific Reports, 6
[48] SGLT2 Inhibitor Empagliflozin Increases Renal NHE3 Phosphorylation in Diabetic Akita Mice: Possible Implications for the Prevention of Glomerular Hyperfiltration
Fu, Yiling
Gerasimova, Maria
Mayoux, Eric
Masuda, Takahiro
Vallon, Volker
DIABETES, 2014, 63 : A132 - A132
[49] The Effect of Renal Impairment on the Pharmacokinetics and Urinary Glucose Excretion of the SGLT2 Inhibitor ASP1941 in Type 2 Diabetes Mellitus Patients
Veltkamp, Stephan A.
Van Dijk, Jan
Krauwinkel, Walter J. J.
Smulders, Ronald A.
DIABETES, 2011, 60 : A309 - A310
[50] TS-071, a Novel, Potent and Selective SGLT2 Inhibitor, Induces Weight Loss and a Reduction in Adipocyte Size in Diet-Induced Obese Rats
Uchida, Saeko
Takahashi, Teisuke
Tomoike, Hideki
Gunji, Emi
Kojima, Naoki
Fukuhara, Namiko
Takano, Kahori
Nakayama, Takashi
Takahashi, Kenzo
DIABETES, 2011, 60 : A274 - A274

← 1 2 3 4 5 →